YORVIPATH

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Romania.

Active ingredients

The drug YORVIPATH contains one active pharmaceutical ingredient (API):

1	Palopegteriparatide UNII G2N64C3385 - PALOPEGTERIPARATIDE
	Palopegteriparatide is a prodrug, consisting of PTH conjugated to a methoxypolyethylene glycol carrier (mPEG) via a proprietary TransCon Linker. PTH and its main metabolite, PTH, have similar affinity to and activation of PTH1R as endogenous PTH. At physiological conditions, PTH is cleaved from palopegteriparatide in a controlled manner to provide a continuous systemic exposure of active PTH.
	Read more about Palopegteriparatide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
YORVIPATH Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H05AA05		H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05A Parathyroid hormones and analogues → H05AA Parathyroid hormones and analogues
Discover more medicines within H05AA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3058691, 3058703, 3058714
FR	Base de données publique des médicaments	60401236, 64364739, 67088616
IT	Agenzia del Farmaco	050966011, 050966023, 050966035
LT	Valstybinė vaistų kontrolės tarnyba	1098161, 1098162, 1098163
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W70238001, W70239001, W70240001
US	FDA, National Drug Code	73362-100, 73362-101, 73362-102